Journal of Practical Hepatology ›› 2025, Vol. 28 ›› Issue (4): 636-640.doi: 10.3969/j.issn.1672-5069.2025.04.040

Previous Articles    

Hepatic artery infusion chemotherapy based on oxaliplatin and raltitrexed in treatment of patients with primary liver cancer

Peng Le, Huang Guye, Xu Lihong   

  1. Guangxi University of Traditional Chinese Medicine, Nanning 530000, Guangxi Zhuang Autonomous Region, China
  • Received:2024-10-29 Online:2025-07-10 Published:2025-07-14

Abstract: Primary liver cancer ( PLC ) is one of the most common cancers in the world and is also the third most common cause of death from malignant tumors. It increases family and social economic burden. In recent years, hepatic artery infusion chemotherapy ( HAIC ) has gained more and more favor in the treatment of patients with PLC due to its excellent efficacy and safety. The raltitrexed and oxaliplatin (RALOX)-HAIC regimen has emerged in this field as the active exploration of domestic scholars get a satisfactory efficacy. In this article, we reviewed the application and prospect of RALOX-HAIC and its combination therapy in dealing with patients with PLC.

Key words: Primary Liver Cancer, Hepatic artery infusion chemotherapy, Raltitrexed/oxaliplatin regimen, Combination therapy